Comparative pharmacoeconomic analysis of metastatic colorectal cancer treatment

Abstract

Every year, the pharmacological market offers new medicines to increase the survival rate and improve the quality of life of patients with cancer. However, while significantly exceeding the cost of existing methods of pharmacotherapy, new technologies often lead to only a small increased efficiency. Budget resources of health care dictate the need for a rational choice of pharmacotherapeutic options for malignant neoplasms that meet the principles of ensuring maximum results and accessibility for the entire population. An important role in solving this problem is played by such a direction of pharmacoeconomic analysis as the “cost-effectiveness” method. Colorectal cancer is one of the three oncological diseases that cause the greatest socio-economic burden for the state, which is associated with the highest costs of the Russian Federation health care system. Concurrently, in the last decade, a much more favorable prognosis has been identified for patients with metastatic colorectal cancer due to the development of effective approaches to antitumor pharmacotherapy. Conducting a pharmacoeconomic review that takes into account both clinical and economic indicators when using classic chemotherapy regimens and new targeted drugs will determine the effectiveness of finances that are spent to combat this malignancy. Additionally, the need to further individualize the therapy of patients suffering from metastatic colorectal cancer and lower prices for modern antitumor drugs is undeniable.

Keywords

colorectal cancer / patients with cancer / antitumor pharmacotherapy / chemotherapy / targeted therapy / cost-effectiveness indicator / budget health resources

References

[1] Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol. 2021;18(10):663–672. DOI: 10.1038/s41571-021-00514-z

[2] Soerjomataram I., Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070 // Nat Rev Clin Oncol. 2021. Vol. 18, No. 10. P. 663–672. DOI: 10.1038/s41571-021-00514-z

[3] Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. Kaprin AD, Stalinskiy VV, Shahzadova AO. editors. Moscow: MNIOI im PA Gercena. filial FGBU NMIC radiologii Minzdrava Rossii; 2020. 239 p. (In Russ.).

[4] Состояние онкологической помощи населению России в 2019 году / под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. Мoсква: МНИОИ им. П.А. Герцена — филиал ФГБУ НМИЦ радиологии Минздрава России, 2020. 239 с.

[5] Andreev DA, Polyakova KI, Zavyalov AA, et al. The main directions of the analysis of economic costs in the provision of oncological care to the population. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):310−317. (In Russ.). DOI: 10.17749/2070-4909.2019.12.4.310-317

[6] Андреев Д.А., Полякова К.И., Завьялов А.А., и др. Основные направления анализа экономических затрат при оказании онкологической помощи населению // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019. Т. 12, № 4. С. 310−317. DOI: 10.17749/2070-4909.2019.12.4.310-317

[7] Feldblum IV, Alyeva MKh, Radionova MV. Complex influence of medico-social and environmental risk factors on the probability of colorectal cancer development. Pacific Medical Journal. 2018;(3):24−28. (In Russ.). DOI: 10.17238/pmj1609-1175.2018.3.24-28

[8] Фельдблюм И.В., Алыева М.Х., Радионова М.В. Комплексное влияние медико-социальных и средовых факторов риска на вероятность развития колоректального рака // Тихоокеанский медицинский журнал. 2018. № 3. С. 24−28. DOI: 10.17238/pmj1609-1175.2018.3.24-28

[9] Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis. JAMA Oncol. 2017;3(4):524–548. DOI: 10.1001/jamaoncol.2016.5688

[10] Fitzmaurice C., Allen C., Barber R.M., et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis // JAMA Oncol. 2017. Vol. 3, No. 4. P. 524–548. DOI: 10.1001/jamaoncol.2016.5688

[11] Blinov DV, Akarachkova ES, Orlova AS, et al. New framework for the development of clinical guide lines in Russia. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(2):125–144. (In Russ.). DOI: 10.17749/2070-4909.2019.12.2.125-144

[12] Блинов Д.В., Акарачкова Е.С., Орлова А.С., и др. Новая концепция разработки клинических рекомендаций в России // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019. Т. 12, № 2. С. 125−144. DOI: 10.17749/2070-4909.2019.12.2.125-144

[13] Omelyanovsky VV, Avksentyeva MV, SuraMV, et al. Approaches to the formation of a unified methodology for calculating incremental indicators “costs/efficiency” on the example of antitumor drugs in the framework of revising the lists of medicines for medical use. Medical technologies. Evaluation and Selection. 2018;(1):10–20. (In Russ.). DOI: 10.17116/medtech12018131110

[14] Омельяновский В.В., Авксентьева М.В., Сура М.В., и др. Подходы к формированию единой методики расчета инкрементных показателей «затраты/эффективность» на примере противоопухолевых препаратов в рамках пересмотра перечней лекарственных препаратов для медицинского применения // Медицинские технологии. Оценка и выбор. 2018. № 1. С. 10–20.

[15] Serpik VG, Yagudina RI, KulikovA Yu. Pharmacoeconomics of innovations or innovations in pharmacoeconomics: a “relative value” analysis instead of a “cost-effectiveness” analysis? Farmakoekonomika: teoriya i praktika. 2019;2:5–8. (In Russ.). DOI: 10.30809/phe.2.2019.1

[16] Серпик В.Г., Ягудина Р.И., Куликов А.Ю. Фармакоэкономика инноваций или инновации в фармакоэкономике: анализ «относительной ценности» вместо анализа «затраты – эффективность»? // Фармакоэкономика: теория и практика. 2019. Т. 7, № 2. С. 5–8. DOI: 10.30809/phe.2.2019.1

[17] Zaplutanov VA, Litovkin AV, Belov VG, et al. Quality of life in elderly and senile cancer patients. PA. Herzen Journal of Oncology. 2016;2:25–28. (In Russ.).

[18] Заплутанов В.А., Литовкин А.В., Белов В.Г., и др. Качество жизни пациентов пожилого и старческого возраста с онкологической патологией // Онкология. Журнал им. А.П. Герцена. 2016. № 2. С. 25–28.

[19] Zadlo J. Cost-effectiveness of new and emerging treatment options for metastatic colorectal cancer. Am J Manag Care. 2018;24(7):118–124.

[20] Zadlo J. Cost-effectiveness of new and emerging treatment options for metastatic colorectal cancer // Am J Manag Care. 2018. Vol. 24, No. 7. P. 118–124.

[21] Sherman SK, Lange JJ, Dahdaleh FS, et al. Cost-effectiveness of maintenance capecitabine and bevacizumab in metastatic colorectal cancer. JAMA Oncology. 2019;5(2):236–242. DOI: 10.1001/jamaoncol.2018.5070

[22] Sherman S.K., Lange J.J., Dahdaleh F.S., et al. Cost-effectiveness of maintenance capecitabine and bevacizumab in metastatic colorectal cancer // JAMA Oncology. 2019. Vol. 5, No. 2. P. 236–242. DOI: 10.1001/jamaoncol.2018.5070

[23] Tryakin AA, Balunov PA. Pharmacoeconomical assessment of the use of targeted therapy and chemotherapy. Medical Council. 2018;19:50–55. (In Russ.) DOI: 10.21518/2079-701X-2018-19-50-55

[24] Трякин А.А., Балунов П.А. Фармакоэкономическая оценка применения таргетной терапии и химиотерапии // Медицинский совет. 2018. Т. 19. С. 50–55. DOI: 10.21518/2079-701X-2018-19-50-55

[25] Fedyanin MYu, Tryakin AA, Rogov VA, et al. Pharmacoeconomical features of the choice of systemic therapy in patients with metastatic colon cancer. Colorectaloncology. 2017;7(2):36–42. (In Russ.). DOI: 10.17650/2220-3478-2017-7-2-36-42

[26] Федянин М.Ю., Трякин А.А., Рогов В.А., и др. Фармакоэкономические особенности выбора системной терапии больных метастатическим раком толстой кишки // Онкологическая колопроктология. 2017. Т. 7, № 2. С. 36–42. DOI: 10.17650/2220-3478-2017-7-2-36-42.

[27] Avksentiev NA, Derkach EV, Pyadushkina EA, Ter-Ovanesov MD. The cost of treatment of metastatic colorectal cancer in the second and subsequent lines of therapy using targeted drugs. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2016;9(2):38–44. (In Russ.). DOI: 10.17749/2070-4909.2016.9.2.038-044

[28] Авксентьев Н.А., Деркач Е.В., Пядушкина Е.А., Тер-Ованесов М.Д. Стоимость лечения метастатического колоректального рака во второй и последующих линиях терапии с использованием таргетных препаратов // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2016. Т. 9, № 2. С. 38–44. DOI: 10.17749/2070-4909.2016.9.2.038-044

[29] Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. OncoTargets and Therapy. 2019;12:2271–2278. DOI: 10.2147/OTT.S194605

[30] Byrne M., Saif M.W. Selecting treatment options in refractory metastatic colorectal cancer // Onco Targets and Therapy. 2019. Vol. 12. P. 2271–2278. DOI: 10.2147/OTT.S194605

[31] Gorchakov SV, Jusudov IV, Vasiliev SV et al. Long-term results and prognostic factors-their influence on the choice of treatment tactics for patients with colorectal cancer with liver metastases. Povolzhsky Oncological Bulletin. 2016;(1):29–37. (In Russ.). DOI: 616.34/.35-006.6-06:616.36-033.2

[32] Горчаков С.В., Правосудов И.В., Васильев С.В., и др. Отдаленные результаты и факторы прогноза – их влияние на выбор тактики лечения больных колоректальным раком с метастазами в печень // Поволжский онкологический вестник. 2016. № 1. С. 29–37. DOI: 616.34/.35-006.6-06:616.36-033.2

[33] Fedenko AA, Tryakin AA, Zhukova LG, et al. Nacional’noe rukovodstvo po lekarstvennomu lecheniju zlokachestvennyh opuholej. Kaprin AD, editor. Moscow; 2020. 408 p. (In Russ.).

[34] Феденко А.А., Трякин А.А., Жукова Л.Г., и др. Национальное руководство по лекарственному лечению злокачественных опухолей / под ред. А.Д. Каприна. Москва, 2020. 408 с.

[35] Huxley N, Crathorne L, Varley-Campbell J, et al. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment. 2017;21(38). DOI: 10.3310/hta21380

[36] Huxley N., Crathorne L., Varley-Campbell J., et al. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation // Health Technology Assessment. 2017. Vol. 21. No. 38. DOI: 10.3310/hta21380

[37] Ungari AQ, Pereira LRL, Nunes AA, Peria FM. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC Cancer. 2017;17:691. DOI: 10.1186/s12885-017-3679-5

[38] Ungari A.Q., Pereira L.R.L., Nunes A.A., Peria F.M. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school // BMC Cancer. 2017. Vol. 17. P. 691. DOI: 10.1186/s12885-017-3679-5

[39] Shida T, Endo Y, Shiraishi T, et al. Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis. Yakugaku Zassi. 2018;138(1):83–90. DOI: 10.1248/Yakushi.17-00159

[40] Shida T., Endo Y., Shiraishi T., et al. Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis // Yakugaku Zassi. 2018. Vol. 138, No. 1. P. 83–90. DOI: 10.1248 / Yakushi.17-00159

[41] Goldstein DA, Chen QS, Iyer T, et al. Bevacizumab for metastatic colorectal cancer: a global cost-effectiveness analysis. Тhe Oncologist. 2017;22(6):694–699. DOI: 10.1634/theoncologist.2016-0455

[42] Goldstein D.A., Chen Q.S., Iyer T., et al. Bevacizumab for metastatic colorectal cancer: a global cost-effectiveness analysis // Тhe Oncologist. 2017. Vol. 22, No. 6. P. 694–699. DOI: 10.1634/theoncologist.2016-0455

[43] Calcagno F, Lenoble S, Lakkis Z, et al. Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice. Libertas Academica. 2016;10:59–66. DOI: 10.4137/CMO.S38335

[44] Calcagno F., Lenoble S., Lakkis Z., et al. Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice // Libertas Academica. 2016. Vol. 10. P. 59–66. DOI: 10.4137/CMO.S38335

[45] Overman MJ, Dermott RM, André T. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability – high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study. The Lanset Oncologi. 2017;18(9):510. DOI: 10.1016/S1470-2045(17) 30638-1

[46] Overman M.J., Dermott R.M., André T. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability – high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study // The Lanset. Oncologi. 2017. Vol. 18, No. 9. P. 510. DOI: 10.1016/S1470-2045(17) 30638-1

[47] Tintelnot J, Stein A. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. World J Gastroenterol. 2019;25(29):3920–3928. DOI: 10.3748/wjg.v25.i29.3920

[48] Tintelnot J., Stein A. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches // World J Gastroenterol. 2019. Vol. 25, No. 29. P. 3920–3928. DOI: 10.3748/wjg.v25.i29.3920

RIGHTS & PERMISSIONS

Petukhova Y.Y., Eliseeva E.V., Apanasevich V.I., Petukhova A.G., Ovodova A.V.